Open-Label Trial of Atomoxetine Hydrochloride in Adults With ADHD
Johnson, Mats ; Cederlund, Mats ; Råstam, Maria LU
; Areskoug, Björn
and Gillberg, Christopher
(2010)
In Journal of Attention Disorders
13(5).
p.45-539
- Abstract
- Background:
While atomoxetine is an established treatment for attention-deficit/hyperactivity disorder in children, few studies have examined its efficacy for adults.
Methods:
Open-label trial of atomoxetine in 20 individuals with ADHD, aged 19-47 years, for 10 weeks, and a total of one year for responders.
Results:
Ten patients met primary efficacy criteria at 10 weeks. Only one patient completed the whole study. Six patients discontinued before 10 weeks and thirteen at 10 weeks or later, mainly because of side-effects (aggression, depressed mood, raised liver enzymes, thyroid hormones, diastolic blood
pressure), decreasing efficacy or non-compliance. ... (More) - Background:
While atomoxetine is an established treatment for attention-deficit/hyperactivity disorder in children, few studies have examined its efficacy for adults.
Methods:
Open-label trial of atomoxetine in 20 individuals with ADHD, aged 19-47 years, for 10 weeks, and a total of one year for responders.
Results:
Ten patients met primary efficacy criteria at 10 weeks. Only one patient completed the whole study. Six patients discontinued before 10 weeks and thirteen at 10 weeks or later, mainly because of side-effects (aggression, depressed mood, raised liver enzymes, thyroid hormones, diastolic blood
pressure), decreasing efficacy or non-compliance.
Conclusion:
Fifty percent responded to treatment, but only one patient (5%) felt sufficient improvement to continue for one year. Dosage may have been too low, and baseline impairment too high, for atomoxetine to have sufficient effect on ADHD symptoms in our group of adults. The majority had few side-effects, but several terminated treatment because of adverse effects. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1457526
- author
- Johnson, Mats
; Cederlund, Mats
; Råstam, Maria
LU
; Areskoug, Björn
and Gillberg, Christopher
- organization
- publishing date
- 2010
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- long-term trial, adults, atomoxetine, ADHD
- in
- Journal of Attention Disorders
- volume
- 13
- issue
- 5
- pages
- 45 - 539
- publisher
- SAGE Publications
- external identifiers
-
- scopus:77649247794
- pmid:19458384
- ISSN
- 1557-1246
- DOI
- 10.1177/1087054709332372
- language
- English
- LU publication?
- yes
- id
- c852ce2b-785e-4392-a142-3672f6a360e1 (old id 1457526)
- date added to LUP
- 2016-04-04 11:20:25
- date last changed
- 2022-01-29 21:41:49
@article{c852ce2b-785e-4392-a142-3672f6a360e1,
abstract = {{Background: <br/><br>
While atomoxetine is an established treatment for attention-deficit/hyperactivity disorder in children, few studies have examined its efficacy for adults. <br/><br>
<br/><br>
Methods: <br/><br>
Open-label trial of atomoxetine in 20 individuals with ADHD, aged 19-47 years, for 10 weeks, and a total of one year for responders. <br/><br>
<br/><br>
Results: <br/><br>
Ten patients met primary efficacy criteria at 10 weeks. Only one patient completed the whole study. Six patients discontinued before 10 weeks and thirteen at 10 weeks or later, mainly because of side-effects (aggression, depressed mood, raised liver enzymes, thyroid hormones, diastolic blood<br/><br>
pressure), decreasing efficacy or non-compliance. <br/><br>
<br/><br>
Conclusion: <br/><br>
Fifty percent responded to treatment, but only one patient (5%) felt sufficient improvement to continue for one year. Dosage may have been too low, and baseline impairment too high, for atomoxetine to have sufficient effect on ADHD symptoms in our group of adults. The majority had few side-effects, but several terminated treatment because of adverse effects.}},
author = {{Johnson, Mats and Cederlund, Mats and Råstam, Maria and Areskoug, Björn and Gillberg, Christopher}},
issn = {{1557-1246}},
keywords = {{long-term trial; adults; atomoxetine; ADHD}},
language = {{eng}},
number = {{5}},
pages = {{45--539}},
publisher = {{SAGE Publications}},
series = {{Journal of Attention Disorders}},
title = {{Open-Label Trial of Atomoxetine Hydrochloride in Adults With ADHD}},
url = {{http://dx.doi.org/10.1177/1087054709332372}},
doi = {{10.1177/1087054709332372}},
volume = {{13}},
year = {{2010}},
}